A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer.

Trial Profile

A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2014

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Jun 2010 Merck and Co added as trial sponsor, trial affiliate and Merck Sharp and Dohme added as trial affiliate, lead trial centres as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Additional lead trial investigator (Haluska F) identified as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top